Shift Pharmaceuticals
Shift Pharmaceuticals is developing Antisense Oligonucleotides as drug candidates for a variety of genetic disorders, including Charcot Marie Tooth Syndrome (CMT1A) and Spinal Muscular Atrophy (SMA). Rather than alleviating certain disease side effects, these molecules “SHIFT” the body’s natural protein production back into alignment effectively addressing the core cause of the disease. We are supported with funding from the NIH, DoD, CMT Research Foundation, and Gwendolyn Strong Foundation.
7-day free trial · no credit card
Verified contacts
2
available on Kipplo
LinkedIn employees
4
1 to 10 range
Open roles
—
no listings
Distinct roles
2
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 2 verified contacts at Shift Pharmaceuticals
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
2 contacts with verified email or phone · masked until revealed.
Showing 1 of 2 verified contacts
Top roles at Shift Pharmaceuticals
2 distinct titles indexed · top 2 shown.
- 1ceo
- 1director of research and development
Sign up to unlock all 2 contacts at Shift Pharmaceuticals
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 2 verified contacts at Shift Pharmaceuticals
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.